[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100556028":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":31,"responsibleParty":49,"collaborators":29,"id":52,"slug":29,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":29,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":59,"minAge":60,"maxAge":29,"enrollmentInfo":61,"targetDuration":29,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":72,"overallStatus":33,"whyStopped":29,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Peking University First Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"68Ga-C1","EXPERIMENTAL","Subjects with suspected or confirmed clear cell renal cell carcinoma will receive an intravenous injection of 68Ga-C1 followed by PET imaging. The subjects will also receive a whole-body 18F-FDG PET\u002FCT scan within a one-week period.",[13],"Drug: 68Ga-C1",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","68Ga-C1 is injected intravenously with a dose of 0.05-0.10 mCi\u002Fkg",[9],[20],"CAIX specific PET imaging",[22],{"name":23,"affiliation":5,"role":24},"Kan Gong","PRINCIPAL_INVESTIGATOR",[26],{"name":23,"role":27,"phone":28,"phoneExt":29,"email":30},"CONTACT","(86)-010-83572075",null,"kan.gong@bjmu.edu.cn",[32],{"facility":5,"status":33,"city":34,"state":35,"zip":36,"country":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"RECRUITING","Beijing","Beijing Municipality","100034","China",{"type":39,"coordinates":40},"Point",[41,42],116.39723,39.9075,{"lat":42,"lon":41},[45],{"name":46,"role":27,"phone":47,"phoneExt":29,"email":48},"Yanyan Yu","+86 1066119025","bdyyll@126.com",{"type":24,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":29,"oldOrganization":29},"GONG Kan","Surgeon","100556028",false,"NCT06519760","68Ga-C1 PET\u002F CT Imaging in Clear Cell Renal Cell Carcinoma","Evaluation of Diagnostic Value of 68Ga-C1 PET\u002F CT Imaging in Clear Cell Renal Cell Carcinoma","Inclusion Criteria:\n\n1. Signed written informed consent；\n2. Age ≥18；\n3. Patients with confirmed or suspected clear cell renal cell carcinoma;\n4. Expected survival ≥6 months.\n\nExclusion Criteria:\n\n1. Renal mass is known to be a metastasis of another primary tumor;\n2. Have other malignancies that require treatment;\n3. Have received chemotherapy, radiotherapy, or immunotherapy within 4 weeks;\n4. Renal insufficiency with glomerular filtration rate (GFR) ≤ 60 mL\u002Fmin\u002F1.73 m²;\n5. Pregnant and lactating women or female patients plan to become pregnant within 6 months;\n6. Uncontrolled psychiatric disorders;\n7. Vulnerable population (e.g., being in detention) or have a serious non-malignant disease (e.g., infectious disease, autoimmune disease, or metabolic disease).",true,"ALL","18 Years",{"count":62,"type":63},200,"ESTIMATED","INTERVENTIONAL",[66],"NA","The goal of this clinical trial is to evaluate the diagnostic value of CAIX protein specific probe 68Ga-C1 in PET\u002FCT imaging in clear cell renal cell carcinoma patients. It will also learn about the safety, tolerability and radiation dosimetry of 68Ga-C1.\n\nResearchers will compare the diagnostic value of 68Ga-C1 PET\u002FCT and 18F-FDG PET\u002FCT in Chinese patients with indeterminate renal masses or confirmed clear cell renal cell carcinoma.",[69,70,71],"Carbonic Anhydrase IX","PET-CT","Clear Cell Renal Cell Carcinoma",[69,9,70,71],"2024-11-05",{"date":75,"type":76},"2024-11-07","ACTUAL",{"date":78,"type":76},"2024-07-30",{"date":80,"type":63},"2026-12-31",{"name":5,"class":6},1]